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Almost all trials with a censored time-to-event outcome
are designed, powered and analysed with a target hazard
ratio for comparing experimental and control treatments
in mind. Differences in survival experience between trial
arms are tested with a logrank test and usually illu-
strated using a Kaplan-Meier plot. We describe this as
an analysis in the probability domain. The focus is often
on estimating survival probabilities at particular times
after randomization.
In the absence of censoring, we would almost certainly
prefer to work in the time domain. We would analyse
times to event directly, summarizing results in terms of
means, SDs and confidence intervals for differences. We
would illustrate the different survival experiences using
comparative scatter plots of times to event, histograms
and the like.
The probability domain paradigm works well in many
cases, but the hazard ratio, as a meaningful summary
measure, requires one crucial assumption: proportional
hazards of the treatment effect. In some recent high-
profile trial reports, the PH assumption has clearly been
invalid. We consider and recommend a general analysis
strategy, relevant to the time domain, that does not
assume PH. It based on the idea of the restricted mean
survival time (RMST). We discuss the motivation, defi-
nition and interpretation of RMST and suggest how it
can be woven into a strategy for time to event trials in
which non-PH is anticipated or discovered.
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